Evidence map›Paper›PMID 40965142›Full record

ArticleJournal of virology2025

Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment.

Yibo Ding, Qiudi Li, Yunlu Sha, Ruilin Si, Chengqian Feng, Mei Liu, Zhanghao Feng, Xutong Ding, Ying Li, Huiyuan Fu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Interferon-mediated regulation of the neurovascular unit in diabetic retinopathy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yibo Ding *Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0002-2544-3882
Qiudi Li *Department of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Yunlu ShaDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Ruilin SiDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Chengqian FengInstitute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China.
Mei LiuDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Zhanghao FengDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Xutong DingDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Ying LiDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Huiyuan FuDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Shiquan LiangDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Qili YaoDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.
Zhenfeng ZhangSchool of Public Health and Emergency Management, Southern University of Science and Technology, Shenzhen, China.ORCID 0000-0002-0013-3685
Feng LiScientific Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.ORCID 0000-0003-3169-6349
Stephan UrbanDepartment of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany.
Hongbo GuoDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.ORCID 0009-0006-9241-1414
Wenshi WangDepartment of Pathogen Biology and Immunology, Jiangsu Key Laboratory of Immunity and Metabolism, Jiangsu International Laboratory of Immunity and Metabolism, Xuzhou Medical University, Xuzhou, China.ORCID 0000-0002-7330-262X

Funding

National Natural Science Foundation of China 32270161Natural Science Foundation of Jiangsu Higher Education Institutions of China 23KJD310005Postgraduate Research & Practice Innovation Program of Jiangsu Province KYCX25_3306,KYCX25_3221,KYCX25_3224,KYCX24_3097Research Grant of Jiangsu Commission of Health, China ZD2021036Starting Grant for Talents of Xuzhou Medical University D2024017,D2021008,D2021007
6 · The paper itself

Abstract

Chronic hepatitis delta virus (HDV) infection causes the most severe form of viral hepatitis. Although humans produce 12 subtypes of interferon-alpha (IFN-α), IFN-α2a has been the only commonly used treatment against HDV. Previously, we characterized eight HDV genotype isolates with varying replication kinetics. Herein, we systematically investigated the antiviral efficacy of IFN-α2a and other IFN-α subtypes against HDV genotypes 1-8 during IMPORTANCE: Chronic hepatitis delta virus (HDV) infection represents the most severe form of viral hepatitis. This study comprehensively evaluated the antiviral efficacy of interferon-alpha (IFN-α) subtypes across eight HDV genotypes during

Indexed as

Adenosine DeaminaseHepatitis D, ChronicHepatitis Delta VirusInterferon-alphaRNA-Binding ProteinsAntiviral AgentsCell Line, TumorDrug Resistance, ViralGenotypeHumansInterferon alpha-2Leukocytes, MononuclearRNA, ViralVirus ReplicationADAR protein, humanAdenosine DeaminaseAntiviral AgentsInterferon-alphaInterferon alpha-2RNA-Binding ProteinsRNA, Viralcell division-mediated spreadde novo infectionHDV genotypesinterferon-alpharesting cells

Identifiers

PMID40965142
PMCPMC12548406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.